<DOC>
	<DOCNO>NCT00408772</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Radiofrequency ablation use high-frequency , electric current kill tumor cell . Giving chemotherapy bevacizumab surgery radiofrequency ablation may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase II trial study well give oxaliplatin capecitabine together bevacizumab follow surgery and/or radiofrequency ablation work treat patient colorectal cancer spread liver remove surgery .</brief_summary>
	<brief_title>Oxaliplatin , Capecitabine , Bevacizumab Followed By Surgery and/or Radiofrequency Ablation Patients With Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate conversion rate nonresectable disease resectable disease patient nonresectable liver metastasis secondary colorectal adenocarcinoma treat neoadjuvant therapy comprise oxaliplatin , capecitabine , bevacizumab follow hepatic resection and/or radiofrequency ablation . - Evaluate progression-free survival patient treat regimen . Secondary - Determine disease-free overall survival patient treat regimen . - Determine toxicity regimen patient . OUTLINE : - Neoadjuvant therapy : Patients receive oxaliplatin IV 2 hour bevacizumab IV 1 hour day 1 oral capecitabine twice daily day 1-14 . Treatment repeat every 3 week 4-6 course absence disease progression unacceptable toxicity conversion resectable disease . - Surgery and/or radiofrequency ablation ( RFA ) : Patients undergo hepatic resection ( without RFA ) tumor deem resectable . Patients stable ( &lt; 8 lesion ) unresectable disease undergo laparoscopic percutaneous RFA . RFA repeat 4-6 week later . - Adjuvant therapy : Beginning 6-8 week surgery and/or RFA , patient may receive adjuvant therapy comprise oxaliplatin , capecitabine , bevacizumab , neoadjuvant therapy , 4 course . After completion study treatment , patient follow every 4 month . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal adenocarcinoma metastatic liver Unresectable liver metastases Measurable disease No evidence extrahepatic metastases No CNS metastases PATIENT CHARACTERISTICS : ECOG performance status 01 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Creatinine ≤ 1.5 time upper limit normal ( ULN ) OR creatinine clearance ≥ 45 mL/min Urinary protein &lt; 2+ dipstick OR &lt; 2 g 24hour urine collection Bilirubin &lt; 2 time ULN SGOT SGPT &lt; 2 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 18 month completion study therapy Able take oral medication ( e.g. , dysphagia malabsorption symptom ) No prior malignancy unless complete remission therapy ≥ 5 year No know allergy study drug No peripheral neuropathy &gt; grade 1 No uncontrolled infection No uncontrolled hypertension No active bleed hemoptysis No serious concurrent illness within past 12 month , include follow : Nonstable coronary artery disease Myocardial infarction Transient ischemic attack Cardiovascular accident PRIOR CONCURRENT THERAPY : Recovered prior therapy At least 28 day since prior major surgery Prior therapy advance disease allow No prior oxaliplatinbased therapy Concurrent maintenance palliative treatment study chemotherapy allow ( e.g. , nutritional transfusional support pain control ) No concurrent corticosteroid except use follow circumstance : As oxaliplatin premedication Anti5HT_3 antiemetic No concurrent cold cap ice mouth rinse No concurrent chemotherapy No placement hepatic artery port regional chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>